Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
When best friends AnnaLee Canario and Dacia Benjamin started taking weight loss drugs together they thought it would be an ...
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...
Both semaglutide and tirzepatide should help people with Type 2 diabetes lower their HbA1c, a measure of blood glucose over ...
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...
Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...
A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...
Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, ...
Zepbound (tirzepatide) is an FDA-approved medication ... How to get Zepbound After signing up, you must complete an online health survey and have an appointment with one of Ro’s affiliated ...
After 72 weeks, 94% (67 of 71) of the 10 mg tirzepatide-treated participants and 96% (73 of 76) of the 15 mg tirzepatide-treated participants reached a bodyweight reduction of at least 5%, compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results